Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Well-differentiated Pancreatic Neuroendocrine Tumor”

48 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 48 results

Early research (Phase 1)WithdrawnNCT02831179
What this trial is testing

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Who this might be right for
Functional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMerkel Cell Carcinoma+26 more
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02230176
What this trial is testing

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Who this might be right for
Pancreatic Neuroendocrine Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris 84
Not applicableStudy completedNCT03616431
What this trial is testing

Pancreatic Cancer Dietary Assessment Study

Who this might be right for
Pancreatic NeoplasmPancreas AdenocarcinomaWell-Differentiated Neuroendocrine Carcinoma+1 more
The Christie NHS Foundation Trust 112
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Study completedNCT00869050
What this trial is testing

Capecitabine and Temozolomide for Neuroendocrine Cancers

Who this might be right for
Neuroendocrine Tumors
Columbia University 41
Testing effectiveness (Phase 2)Study completedNCT00781911
What this trial is testing

Cixutumumab (IMC-A12) in Islet Cell Cancer

Who this might be right for
CarcinomaNeuroendocrine Tumors
Eli Lilly and Company 43
Post-approval studies (Phase 4)Study completedNCT01525550
What this trial is testing

The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Who this might be right for
Well-differentiated Pancreatic Neuroendocrine Tumor
Pfizer 106
Testing effectiveness (Phase 2)Active Not RecruitingNCT03891784
What this trial is testing

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Who this might be right for
Advanced Digestive System Neuroendocrine NeoplasmDigestive System Neuroendocrine TumorForegut Neuroendocrine Tumor+6 more
University of Washington 20
Post-approval studies (Phase 4)Study completedNCT02842749
What this trial is testing

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Who this might be right for
Pancreatic Neuroendocrine Tumors
Novartis Pharmaceuticals 61
Testing effectiveness (Phase 2)Study completedNCT02806648
What this trial is testing

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

Who this might be right for
Pancreatic Neuroendocrine Cancer
Grupo Espanol de Tumores Neuroendocrinos 21
Very early researchActive Not RecruitingNCT04544098
What this trial is testing

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Who this might be right for
Neuroendocrine TumorsLiver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center 10
Not applicableUnknownNCT03896958
What this trial is testing

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Who this might be right for
Cancer, All TypesCancer of LiverCancer of Stomach+42 more
SpeciCare 1,000
Testing effectiveness (Phase 2)Ended earlyNCT01215578
What this trial is testing

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic NeoplasmsAdvanced Disease+1 more
Assistance Publique - Hôpitaux de Paris 33
Testing effectiveness (Phase 2)UnknownNCT02294006
What this trial is testing

Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs

Who this might be right for
Well Differentiated Pancreatic Endocrine Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 26
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Testing effectiveness (Phase 2)Study completedNCT02132468
What this trial is testing

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Who this might be right for
Neuroendocrine Tumors
Mateon Therapeutics 18
Testing effectiveness (Phase 2)WithdrawnNCT02108782
What this trial is testing

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Who this might be right for
GastrinomaGlucagonomaInsulinoma+3 more
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Active Not RecruitingNCT03351296
What this trial is testing

Two Chemotherapy Regimens Plus or Minus Bevacizumab

Who this might be right for
Pancreatic Cancer
Gustave Roussy, Cancer Campus, Grand Paris 140
Not applicableLooking for participantsNCT07429851
What this trial is testing

CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Carcinoma of LungNeuroendocrine Carcinoma of Thymus
European Institute of Oncology 34
Load More Results
116